secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001564590-23-002306
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind reports 2022 total revenues of $100M, up 32% YoY; Tyvaso DPI royalties $16M
--------------------------------------------------------------------------------

- Q4 2022 total revenues $36.1M (+188% YoY); full-year $99.8M (+32% vs 2021).
- Afrezza net revenue $43.3M in 2022 (+11%); V-Go contributed $12.9M after Q2 acquisition.
- Tyvaso DPI royalties $15.6M in 2022 ($9.1M in Q4); $37.9M manufacturing revenue deferred.
- Cash and investments $172.8M at Dec 31, 2022; INHALE-1 pediatric trial 50% enrolled.
- Inhaled clofazimine (MNKD-101) to enter adaptive Phase 2/3 study in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000156459023002306/0001564590-23-002306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000156459023002306/mnkd-8k_20230223.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-002306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer